- Morning Sickness
- Drugs in Pregnancy
- Alcohol, Nicotine, Substance Use
- Folic Acid
- Breastfeeding & Drugs
- Cancer in Pregnancy
- HIV and HIV Treatment
- Conditions in Pregnancy
- Infectious Diseases in Pregnancy
- Nutrition
- Occupational & Environmental Exposures
- Pharmacokinetics/ Drug Metabolism
- PregTox
- The ReproPsych Group
- CAS Newsletter
Our Helplines
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
St. John's,NL
2013 FACE meeting
Orlando, Florida
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting
.
-
Jul192012
-
Mar292012
-
Jul282011
-
Jan272011
- Read more in our News Archive
Current Studies at Motherisk
-
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
-
Pregnancy in Women with Multiple Sclerosis
-
Environmental Exposures and Children's Health
-
Alcohol Use during Pregnancy
-
Control of Hypertension in Pregnancy Study
-
Folic Acid Before and During Pregnancy
-
Lamisil in Pregnancy
-
Meridia in Pregnancy
-
Autoimmune Diseases in Pregnancy Project
Anti-infectives: Antivirals
Motherisk Research
-
CMAJ. May 13, 2003; 168(10)
Koren G, King S, Phillips E: Ribavirin in the treatment of SARS: A new trick for an old dog? -
J Pediatr Inf Dis 9:S106-S107, 1990. No abstract available.
Koren G: Studying the safety of ribavirin in human pregnancy. -
Reprod Toxicol 5: 79-81, 1991
Levy M, Pastuszak A, Koren G: Fetal outcome following intrauterine amantadine exposure. -
Reprod Toxicol (In Press).
Pandit PB, Jeffries AL, Landes A, Kumar I, Chitayat D, Koren G; Tibial Hemimelia and Tetralogy of Fallot Associated with First Trimester Exposure to Amantadine. A Case Report.












![Validate my RSS feed [Valid RSS]](/images/rssValid.png)